Eric Dean, MD
Medical Oncology · Kirkland, WANPI 1366632671
Payments from drug & device makers
What this record shows
This record is dominated by education: $54 of the $81 with a category attached, or 67.0%. 4 manufacturers reported payments, led by EMD Serono, Inc. at 33.0% of the total. That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.
Across 4 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$27
- Myovant Sciences Inc.$24
- Merck$18
- Gilead$12
Across 4 payments — averaging $12,303 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$49K
- Merck$500
What the payments were for
- Food & beverage$2733%
- Education$5467%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $24 |
| Merck | 1 | $18 |
| Gilead | 1 | $12 |
How this compares
$81 in reported general payments places this provider in the 15th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $287,442 |
| CalquenceAcalabrutinib Maleate | 13 | $213,917 |
| ImbruvicaIbrutinib | 13 | $207,833 |
| Abiraterone Acetate | 173 | $101,038 |
| Imatinib Mesylate | 14 | $64,020 |
| EliquisApixaban | 30 | $30,940 |
| Prednisone | 185 | $687 |
| Oxycodone Hcl | 35 | $533 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $455 |
| Acyclovir | 43 | $400 |
| Dexamethasone | 28 | $367 |
| Prochlorperazine Maleate | 28 | $356 |
| Potassium Chloride | 31 | $355 |
| Hydroxyurea | 13 | $313 |
| Ondansetron Hcl | 23 | $274 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Kirkland
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Joseph YeOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.